cambridge.org/psm

Original Article

Cite this article: Dekkers GWF, Broeren MAC, Truijens SEM, Kop WJ, Pop VJM (2020). Hormonal and psychological factors in nausea and vomiting during pregnancy. *Psychological Medicine* **50**, 229–236. https://doi.org/10.1017/ S0033291718004105

Received: 30 April 2018 Revised: 11 December 2018 Accepted: 18 December 2018 First published online: 30 January 2019

Key words:

Depression; hCG; nausea; NVP; pregnancy; thyroid function

Author for correspondence: Victor J.M. Pop, E-mail: V.J.M.Pop@uvt.nl

© Cambridge University Press 2019



Hormonal and psychological factors in nausea and vomiting during pregnancy

Guus W.F. Dekkers¹, Maarten A.C. Broeren², Sophie E.M. Truijens³, Willem J. Kop¹ and Victor J.M. Pop¹

¹Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands; ²Laboratory of Clinical Chemistry and Haematology, Máxima Medical Centre, Veldhoven, The Netherlands and ³Department of Obstetrics and Gynaecology, Máxima Medical Centre, Veldhoven, The Netherlands

Abstract

Background. The aetiology of nausea and vomiting during pregnancy (NVP) is multifactorial, but the relative contribution of biological and psychological determinants is insufficiently understood. We examined the association of human chorionic gonadotropin (hCG), thyroid hormones (thyroid-stimulating hormone and thyroxin) and psychological factors with NVP. **Methods.** Blood chemistry and psychological measures were obtained in 1682 pregnant women participating in the Holistic Approach to Pregnancy and the first Postpartum Year (HAPPY) study between 12 and 14 weeks of gestation. The presence of NVP was measured using the Pregnancy-Unique Quantification of Emesis scale. Depressive symptoms were assessed using the Edinburgh Depression Scale. Multivariable logistic regression analyses were used to investigate the independent role of hCG, thyroid hormones and depression as related to NVP, adjusting for age, body mass index, education, parity, smoking status, unplanned pregnancy and history of depression.

Results. Elevated levels of NVP were observed in 318 (18.9%) participants. High hCG levels [odds ratio (OR) = 1.47, 95% confidence interval (CI) = 1.11-1.95], elevated depressive symptoms in the first trimester (OR = 1.67, 95% CI = 1.15-2.43) and a history of depression (OR = 1.53, 95% CI = 1.11-2.11) were independently related to high NVP. Multiparity (OR = 1.47, 95% CI = 1.12-1.92) and younger age (OR = 0.91, 95% CI = 0.87-0.94) were also associated with high NVP, whereas (sub)clinical hyperthyroidism was not related to high NVP.

Conclusions. The current study is the first to demonstrate that a combination of hCG hormone and psychological factors are independently related to nausea and vomiting during early pregnancy.

Introduction

Nausea and vomiting are among the most common symptoms during pregnancy, affecting 50–90% of all pregnant women (O'Donnell *et al.*, 2016). Nausea and vomiting during pregnancy (NVP) starts at the beginning of the first trimester, peaks around 9 weeks and usually resolves after 20 weeks of gestation (Klebanoff *et al.*, 1985; Gadsby *et al.*, 1993; Lacroix *et al.*, 2000). The most severe form of NVP, hyperemesis gravidarum (HG), affects about 0.3–1% of pregnant women (Niebyl, 2010) and these women are often hospitalised because of severe weight loss and dehydration (Jueckstock *et al.*, 2010).

Although NVP is regarded as a physiological and self-limiting process in most cases, around 35% of pregnant women experience the NVP symptoms as interfering with their daily activities (Attard *et al.*, 2002; Andersson *et al.*, 2004; Niebyl, 2010). High levels of NVP are associated with lower quality of life (QOL), reduced work productivity, time loss from work and increased use of healthcare resources (Gadsby *et al.*, 1993; Attard *et al.*, 2002).

The aetiology of NVP is poorly understood, but thought to be multifactorial (O'Donnell *et al.*, 2016). Endocrine factors have been related to NVP. Since the clinical course of NVP symptoms shows a similar pattern as the increase of human chorionic gonadotropin (hCG) levels during the first trimester, higher levels of hCG have been associated with (more severe forms of) NVP (Niebyl, 2010; O'Donnell *et al.*, 2016). However, different findings mitigate against the hCG hypothesis as the sole aetiological factor of NVP. For example, many pregnant women with high hCG levels do not suffer from severe NVP and a substantial proportion of women with severe NVP continue to have symptoms beyond the first trimester when hCG levels are rapidly decreasing. Furthermore, the few studies that investigated a possible relationship between hCG and NVP have methodological flaws and often used small samples (O'Donnell *et al.*, 2016). Therefore, the exact relation between hCG and NVP remains to be determined.

A proposed mediating mechanism for the association between hCG and NVP is the effect of hCG on thyroid function because of the structural similarity between beta hCG and thyroid-stimulating hormone (TSH). This is reflected in the finding of lower TSH levels and elevated thyroxin (FT4) levels when hCG levels increase in normal pregnancy (Verberg *et al.*, 2005). However, the exact relation between thyroid function and NVP in healthy women is poorly investigated and remains unclear. HG has been reported to occur more frequently in women with severe hyperthyroidism (low TSH and high FT4) during early gestation (Tan *et al.*, 2002). Other factors associated with the incidence of NVP are primigravida (Jueckstock *et al.*, 2010; Latva-Pukkila *et al.*, 2010), multiple (twin or higher) gestation (Yates, 2004), larger placentae (Gadsby *et al.*, 1997; Niebyl, 2010), nausea and vomiting in a previous pregnancy (Gadsby *et al.*, 1997; Niebyl, 2010), heritability (Gadsby *et al.*, 1997; Yates, 2004; Vikanes *et al.*, 2010) and insufficient vitamin (B) intake (Källén *et al.*, 2003; Latva-Pukkila *et al.*, 2010; Niebyl, 2010).

In addition to biological processes involved in NVP, evidence indicates that psychosocial factors contribute to NVP. Depression and anxiety disorders are associated with several somatic symptoms, including nausea and vomiting (Walker et al., 1990; Kelly et al., 2001; Haug et al., 2002). During pregnancy, the association of depression and anxiety with NVP has been confirmed in several studies (Chou et al., 2003; Andersson et al., 2004; Swallow et al., 2004). However, surprisingly few studies have adjusted for other psychosocial factors. For example, unplanned and undesired pregnancies (Buckwalter and Simpson, 2002), negative partner relationships, stressful life events (Swallow et al., 2004), a history of migration (Jueckstock et al., 2010), lower education, younger age, eating disorders, overweight (Klebanoff et al., 1985; Jueckstock et al., 2010) and non-smoking (Gadsby et al., 1997; Källén et al., 2003; Jueckstock et al., 2010) have been associated with higher NVP symptoms.

The public health implication of NVP is substantial because approximately one in three women report NVP symptoms that interfere with daily activities (Attard et al., 2002; Andersson et al., 2004; Niebyl, 2010). Understanding the mechanisms involved in NVP may have implications for health policy since NVP may result in increased health care utilisation and time loss from work (Gadsby et al., 1993; Attard et al., 2002). Currently, only limited treatment options exist for all but the most severe NVP (Locock et al., 2008). It appears that women with less severe NVP would benefit from greater acknowledgement of the distress NVP causes them. If both psychological and biological factors contribute to NVP, then an integrated health care approach is likely to be successful. Prior research in NVP has not simultaneously investigated biological and psychological factors. Moreover, small sample sizes and lack of adjustment for possible confounding factors limit the current knowledge of NVP.

The primary goal of this study was to evaluate in a large sample of pregnant women whether biological factors such as hCG and thyroid hormones (TSH and FT4) are related to NVP. Secondly, we evaluated a possible relation between depressive symptoms and NVP. Finally, we explored the combined association of biological and psychological factors with NVP.

Methods

Participants

The women of the current study participated in the Holistic Approach to Pregnancy and the first Postpartum Year (HAPPY) study, of which the design was described in details previously (Truijens *et al.*, 2014). The HAPPY study investigated

general well-being during gestation, also in relation to thyroid function. Dutch-speaking women from 18 years or older and in the first trimester of a singleton pregnancy were eligible for the study. Exclusion criteria were current psychiatric disorders other than depression or anxiety (e.g. schizophrenia, borderline, bipolar disorder) and chronic health disorders (e.g. endocrine disorder) [see Truijens *et al.* (2014) for additional details related to inclusion and exclusion criteria].

Procedure

Women who met the inclusion criteria were invited by their community midwife to participate in the HAPPY study. Of the 3160 eligible women, 72% (2275) gave written informed consent (Truijens et al., 2014). An additional tube of blood was drawn during standard blood assessments between 10 and 12 weeks of gestation for thyroid function evaluation. Six months after starting the HAPPY study (when the first women were included), it was decided to additionally determine hCG. Therefore, the present analyses were based on the 1776 women in whom both thyroid hormones and hCG were assessed. The gestational age was calculated from the date of the last menstrual cycle and from an ultrasound scan during what was presumed to be the 12th week of pregnancy. If a discrepancy of more than 7 days was seen between these two measurements, a second ultrasound scan was performed within 2 weeks to reassess gestational age. Participants completed the baseline questionnaires between 12 and 14 weeks of gestation [median (Md) = 13, inter-quartile range = 13-14; mean (M) = 13.54, standard deviation (s.D.) = 1.74]. Incomplete questionnaires were returned by 94 women. This left a sample of 1682 women suitable for data analysis (95% response rate), in whom both thyroid hormones and hCG were assessed, and who completed all questionnaires.

The HAPPY study was approved by the Ethics Review Board of Tilburg University and the Medical Ethical Committee of the Máxima Medical Centre Veldhoven.

Biological and psychological assessments

NVP

The Pregnancy-Unique Quantification of Emesis (PUQE) scale was used to assess NVP (Koren et al., 2002). The PUQE is a selfreport questionnaire consisting of three items with five answer categories measuring the physical symptoms nausea, vomiting and retching over the past 12 h. The three-item PUQE is a reliable instrument to determine the severity of NVP (Koren et al., 2001, 2002). The Cronbach's α , reflecting the internal consistency of the Dutch PUQE, was $\alpha = 0.67$ in the current study. The PUQE was used to assess NVP during the first trimester of pregnancy, consistent with the methods described by Lacasse and colleagues (2008). The total score of the PUQE ranges from 3 to 15, with higher scores reflecting more severe NVP (Ebrahimi et al., 2009). Since there is no widely established approach to measure the severity of symptoms of NVP, the PUQE scores were used as a continuous variable in the current study. High NVP, indicating the presence of elevated NVP symptoms, was defined as PUQE score >M + 1 s.d. (≥ 9). There was no significant difference in the mean number of weeks of gestation at completion of the questionnaires between the 318 women with high NVP (M =13.60, s.D. = 1.72) compared to the 1364 women without high NVP (M = 13.53, s.p. = 1.74): t = 0.65, p = 0.52, d = 0.040. Furthermore, there was also no significant difference in use of antibiotics or painkillers between the groups of woman with or without high NVP (data not shown).

In addition to the PUQE, the severity of NVP symptoms was also derived from a 57-item symptom checklist inquiring about the most common complaints during the first trimester of pregnancy (such as headache, back-pain, pelvic-pain, nausea and vomiting). NVP-related items were: 'During the previous weeks of pregnancy, did you have symptoms of: 1. Nausea; 2. Nausea and vomiting?'. Women were asked to respond on a five-point Likert scale to these questions. The sum score of these two items correlated highly with the PUQE (r = 0.86, p < 0.001), indicating concurrent validity.

Between 12 and 14 weeks of gestation, before completing the PUQE, women were also asked whether they encountered serious medical problems during the first trimester of pregnancy that needed referral to a general practitioner (GP) and/or a gynaecologist for additional medical evaluation beyond regular monitoring by licensed midwives. This information was used to evaluate the possible occurrence of HG.

HCG and thyroid function

HCG, TSH, FT4 and thyroid peroxidase antibodies (TPO-Ab) were measured in lithium-heparin plasma using electrochemiluminescence assays (Cobas® e 601, Roche Diagnostics, Mannheim Germany). The within-laboratory coefficients of variation are: HCG: 3.1%; TSH: 2.1%; FT4: 3.5% and TPO-Ab: 7.1%. For hCG, levels ranged from 3500 to 310 000 mIU/mL. Because no specific reference range for hCG during pregnancy exists, we divided log hCG in quartiles, with high hCG defined as a hCG level in the upper quartile (hCG 75th percentile = 77 250 mIU/mL). Reference ranges of thyroid hormones during pregnancy are population dependent and are influenced by the applied assays (Medici et al., 2015). Therefore, the reference ranges of TSH and FT4 were determined by using the 2.5th and 97.5th percentiles as lower and upper reference limit assessed in TPO-Ab negative women (≤ 35 IU/mL, *n* = 1528). Between 12 and 14 weeks of gestation reference ranges of 0.21-4.04 mU/L for TSH and 11.52 -18.09 pmol/L for FT4 were obtained. Based on these reference ranges, groups with various thyroid (dys)function were discriminated: euthyroid women (TSH and FT4 both within reference range), overt hypothyroidism (TSH > 97.5th and FT4 < 2.5th percentile), subclinical hypothyroidism (TSH > 97.5th percentile and FT4 within normal reference range), overt hyperthyroidism (TSH < 2.5th and FT4 > 97.5th percentile) and subclinical hyperthyroidism (TSH < 2.5th percentile and FT4 within reference range).

Depression

The Edinburgh Depression Scale (EDS) was used to measure symptoms of depression during the first trimester (Cox *et al.*, 1996). The EDS is the most widely used self-rating scale in the perinatal period to assess depressive symptoms. The EDS has previously been validated in the Netherlands during the postpartum period and for use during pregnancy with trimester specific cut-off values (Pop *et al.*, 1992; Bergink *et al.*, 2011). According to Bergink and colleagues (2011), the EDS has good internal consistency during pregnancy, with a Cronbach's α coefficient reported of $\alpha = 0.82$. Higher EDS scores indicate more depressive symptoms. A cut-off value of ≥ 11 gives the best combination of sensitivity, specificity and positive predictive value for syndromal depression during the first trimester of pregnancy (Bergink *et al.*, 2011). Hence, to define elevated depressive symptoms

(current depression), we used a cut-off value of EDS \ge 11, in addition to using continuous EDS scores. Cronbach's α of the EDS was $\alpha = 0.83$ in the current study.

Covariates

Self-report data were used to document age, height, weight, education level, smoking status and use of medication. Body mass index (BMI) was calculated as kg/m^2 . Information regarding a history of depression, unplanned pregnancy and parity was also obtained using questionnaires (Truijens *et al.*, 2014).

Statistical analyses

Data are presented as mean ± standard deviation (s.D.) or frequency and percentage of total sample (%). The EDS and PUQE were normally distributed whereas hCG, TSH and FT4 were skewed and log-transformed (log 10) prior to statistical analyses. Considering the high number of women with complete data, the 94 participants with missing data on any of the variables were excluded from the analyses. Except for a significant younger age of these 94 women and a lower percentage of high level of education compared to respondents (small effect sizes), no differences in basic characteristics were found (data not shown). Univariate associations were explored between all variables. Pearson correlations were calculated for continuous variables (i.e. PUQE score, hCG, FT4, TSH, EDS score, age and BMI). Independent samples t tests were used for analysing dichotomous variables (i.e. history of depression, education level, smoking status, unplanned pregnancy and parity). Additionally, women were divided into subgroups based on hCG quartiles, thyroid (dys) function and the cut-off for depression. Possible differences in mean scores between groups were examined using independent samples t tests (two-tailed) or analysis of variances. To explore associations between categorical variables χ^2 tests were used. Since large samples easily result in statistically significant differences between subgroups, effect sizes according to Cohen (1992) are reported in addition to two-sided *p*-values. The magnitude of effect sizes is described as small, medium and large based on Pearson correlations of 0.1, 0.3 and 0.5 and for t tests based on Cohen's d of 0.2, 0.5 and 0.8, respectively.

Finally, a multiple logistic regression analysis [odds ratio (OR); 95% confidence interval (CI)] was conducted to test a psychobiological model with high NVP symptoms as outcome (dependent) variable. Depression, hCG and thyroid function were included as independent variables, adjusting for confounding variables (history of depression, age, BMI, education level, smoking status, unplanned pregnancy and parity).

Statistical analyses were performed using SPSS (Statistical Package for Social Sciences version 24; IBM, Chicago, IL, USA).

Results

Participant characteristics

Table 1 presents the demographic and clinical characteristics of the 1682 participating women included in this study.

High NVP (defined as PUQE ≥ 9) was reported by 318 (18.9%) women. The mean PUQE score was 6.24 (s.d. = 2.71). A total of 252 women (15.0%) were referred to the GP and/or gynaecologist because of symptoms requiring additional medical attention. Of these referrals, 61 women (3.6% of the total sample) reported severe problems with nausea and vomiting. These 61

 Table 1. Characteristics of N = 1682 pregnant women included in the current study

Characteristic	Mean (s.p.) or n (%)	Range
PUQE score	6.24 (2.71)	3–15
High PUQE score (≥9, indication of high NVP)	318 (18.9)	
Referral to GP and/or gynaecologist because of		
Severe NVP symptoms	61 (3.6)	
HG	6 (0.4)	
hCG (mIU/mL)	65 447.50 (35 184.59)	3500-310 000
High hCG (highest quartile)	420 (25.0)	
Thyroid (dys)function		
Euthyroid	1575 (93.7)	
Overt hypothyroidism	9 (0.5)	
Subclinical hypothyroidism	58 (3.4)	
Overt hyperthyroidism	16 (1.0)	
Subclinical hyperthyroidism	24 (1.4)	
EDS score	4.48 (4.27)	0–25
High EDS score (≥11, indication of depression)	172 (10.2)	
History of depression	276 (16.4)	
Age (years)	30.45 (3.70)	19–42
BMI (kg/m ²)	23.84 (3.96)	16.00-41.73
Education level		
Low/medium	615 (36.6)	
High	1067 (63.4)	
Smoking	116 (6.9)	
Unplanned pregnancy	112 (6.7)	
Parity		
Primiparous	824 (49.0)	
Multiparous	858 (51.0)	

s.b., standard deviation; %, percentage; PUQE, Pregnancy-Unique Quantification of Emesis scale; high PUQE score, ≥ 9 is an indication of high NVP (based on M+1 s.b.); GP, general practitioner; NVP, nausea and vomiting during pregnancy; HG, hyperemesis gravidarum; high hCG, defined as hCG level in upper quartile; euthyroid, TSH and FT4 both within reference range; overt hypothyroidism, TSH > 97.5th and FT4 > 25.th and FT4 < 2.5th percentile; subclinical hypothyroidism, TSH > 97.5th percentile; subclinical hypothyroidism, TSH > 97.5th percentile; subclinical hypothyroidism, TSH > 2.5th and FT4 sibclinical hypothyroidism, TSH < 2.5th and FT4 > 97.5th percentile; subclinical hypothyroidism, TSH < 2.5th and FT4 > 97.5th percentile; subclinical hypothyroidism, TSH < 2.5th and FT4 sibclinical hypothyroidism, TSH < 0.5th percentile; subclinical hypothyroidism, TSH < 0.5th percentile; sibclinical hypothyroidism, TSH

women had significantly higher mean PUQE scores (M = 10.74, s.D. = 2.32) compared to the 1430 women who did not report a serious medical problem (M = 6.03, s.D. = 2.58): t = 14.02, p < 0.001, d = 1.920. Six of these 61 women were hospitalised because excessive weight loss and dehydration due to severe vomiting during the first trimester. These women were classified as having experienced HG (6/1682 = 0.4%).

A total of 420 (25.0%) women had high hCG levels (defined as hCG level in the upper quartile; hCG 75th percentile = 77 250 mIU/mL). Significant correlations were observed between hCG with TSH (r = -0.21, p < 0.001) and FT4 (r = 0.25, p < 0.001). TSH was inversely correlated with FT4 (r = -0.37, p < 0.001). In total there were 1575 euthyroid women and 107 (6.3%) women with different classes of thyroid dysfunction (see Table 1).

The mean EDS score was 4.48 (s.D. = 4.27) and 172 (10.2%) women met criteria for current depression (EDS \ge 11).

A history of depression was reported by 276 (16.4%) of the participants.

Association between hCG and thyroid (dys)function with NVP

PUQE scores were significantly related to hCG levels (r = 0.06, p = 0.022). As shown in Table 2, the mean PUQE scores increased in the highest hCG quartiles, but the difference was not significant [$F_{(3,1678)} = 2.13$, p = 0.094]. Women with high hCG (defined as hCG level in the upper quartile; n = 420) reported significantly more often high NVP (PUQE score ≥ 9) compared to the women who did not have high hCG levels (defined as hCG level in lower three quartiles; n = 1262): OR = 1.42, 95% CI = 1.08–1.85. Moreover, the six women with HG were not well identified based on hCG (one hCG level of 250 000 mIU/mL, one hCG level of 125 000 mIU/mL and four hCG levels of <100 000 mIU/mL).

Table 2. Association between hCG with PUQE scores, N = 1682

	Range log hCG	п	Mean PUQE score (s.d.)	<i>n</i> high NVP (%) (<i>n</i> = 318)
First log hCG quartile (lowest)	3.54-4.63	436	6.13 (2.71)	74 (17.0)
Second log hCG quartile	4.64-4.76	396	6.08 (2.62)	67 (16.9)
Third log hCG quartile	4.76-4.89	430	6.24 (2.80)	80 (18.6)
Fourth log hCG quartile (highest)	4.89-5.49	420	6.51 (2.69)	97 (23.1)*

PUQE, Pregnancy-Unique Quantification of Emesis scale; s.b., standard deviation; high NVP = PUQE score ≥ 9 (based on M + 1 s.b.); %, percentage of women with high NVP in hCG quartile; $*\chi^2$ test with Yates continuity correction for hCG (high = upper quartile; low = lower three quartiles) and NVP (high = PUQE score ≥ 9), p < 0.05.

Table 3. PUQE scores and number of women according to a history of depression and EDS cut-off for depression between 12 and 14 weeks of gestation, N = 1682

Depression pattern subgroup	п	Mean PUQE score (s.d.)	<i>n</i> high NVP (%) (<i>n</i> = 318)
Group 1 (history of depression—/current depression—)	1298	6.02 (2.60)	218 (16.8)
Group 2 (history of depression+/current depression-)	212	6.69 (2.85)	50 (23.6)
Group 3 (history of depression-/current depression+)	108	7.38 (3.25)**	30 (27.8)
Group 4 (history of depression+/current depression+)	64	7.38 (2.46)**	20 (31.3)

PUQE, Pregnancy-Unique Quantification of Emesis scale; EDS, Edinburgh Depression Scale; s.b., standard deviation; high NVP, PUQE score \geq 9 (based on M + 1 s.b.); %, percentage of women with high NVP in subgroup of depression pattern; current depression, EDS score \geq 11 is an indication of depression in the first trimester according to Bergink and colleagues (2011); **a two-way between-groups analysis of variance revealed only a significant main effect for depression between 12 and 14 weeks of gestation (current depression+), p < 0.001.

PUQE scores were inversely related to TSH levels (r = -0.07, p = 0.004) and not with FT4 levels (r = 0.04, p = 0.15). The mean PUQE scores did not differ significantly between the different subgroups of thyroid (dys)function (data not shown). Also, no significant differences were found in the prevalence of high NVP between the thyroid dysfunction subgroups.

Association of depression with NVP

Depressive symptoms correlated positively with NVP (r = 0.23, p < 0.001). Women with depression between 12 and 14 weeks of gestation (defined as EDS score ≥ 11 , n = 172) had significantly higher mean PUQE scores (M = 7.38, s.D. = 2.97) compared to those with low depression scores (n = 1510, M = 6.11, s.D. = 2.65): t = 5.86, p < 0.001, d = 0.451.

Women who reported a history of depression had significantly higher mean EDS scores between 12 and 14 weeks of gestation (n = 276, M = 6.59, s.d. = 5.04) compared to those who did not report such an episode (n = 1406, M = 4.07, s.d. = 3.97): t = 7.86, p < 0.001 d = 0.555. Women who reported a history of depression reported higher PUQE scores (M = 6.85, s.d. = 2.77), compared to those who did not (M = 6.12, s.d. = 2.68): t = 4.09, p < 0.001, d = 0.268. Table 3 displays results for participants with current depression and/or a history of depression.

As shown in Table 3, the mean PUQE scores were the lowest in the reference group (group 1: no history of depression and no current depression) and the highest in group 3 and group 4 (current depression groups). A two-way between-groups analysis of variance revealed only a significant main effect for depression between 12 and 14 weeks of gestation, $F_{(1,1678)} = 19.31$, p < 0.001, $\eta_p^2 = 0.011$. The main effect for a history of depression and the interaction effect were not significant (data not shown). Moreover, we also explored the percentage of women with high NVP for each of the four depression pattern subgroups. A χ^2 test revealed a significant association between subgroup and high NVP, χ^2 (3, N = 1682) = 18.71, p < 0.001, V = 0.105. Post-hoc analyses showed significantly less than expected women reporting high NVP in the reference group. However, in the groups with a current depression (groups 3 and 4) a significantly higher percentage of women reported high NVP.

Multivariable analyses

A two-way between-groups analysis of variance was used to investigate the relation of a combination of high hCG (hCG upper quartile used as cut-off) and depression (EDS score ≥11 used as cut-off) between 12 and 14 weeks of gestation with NVP symptoms as dependent variable. Figure 1 shows mean PUQE scores for the four subgroups that were formed; group 1: women without elevated hCG and without depression [hCG-/D-, M = 6.03, standard error of the mean (S.E.M.) = 0.08], group 2: women with high hCG and without depression (hCG+/D-, M = 6.36, S.E.M. = 0.14), group 3: women without high hCG and with depression (hCG-/D+, M = 7.22, s.e.m. = 0.27) and group 4: women with high hCG and with depression (hCG+/D+, M =7.82, s.e.m. = 0.39). As can be seen in Fig. 1, mean PUQE scores were the lowest in group 1 (hCG-/D-) and the highest in group 4 (hCG+/D+). A main effect for depression was found, $F_{(1,1678)} = 29.18$, p < 0.001, $\eta_p^2 = 0.017$. The main effect for high hCG and the interaction effect were not significant (data not shown).

A multiple logistic regression analysis with high NVP (PUQE ≥ 9 used as cut-off) as dependent variable, and high hCG (hCG upper quartile used as cut-off), (sub)clinical hyperthyroidism and depression between 12 and 14 weeks of gestation (EDS score ≥ 11 used as cut-off) as independent variables was performed, adjusting for history of depression, age, BMI, education level, smoking status, unplanned pregnancy and parity. Because evidence suggests that NVP occurs more frequently in women with hyperthyroidism during early gestation, (sub)clinical hyperthyroidism (n = 40) was entered as an additional covariate in the model [i.e. women with overt hyperthyroidism (TSH < 2.5th and FT4 > 97.5th percentile) or subclinical hyperthyroidism (TSH < 2.5th percentile and FT4 within reference range)].

10.00 (regul) e000 e0

Fig. 1. The severity of NVP symptoms as related to elevated hCG and/or depressive symptoms. NVP, nausea and vomiting during pregnancy; PUQE, Pregnancy-Unique Quantification of Emesis scale; hCG+ = high hCG, defined as hCG level in the upper quartile; D+ = depression, defined as EDS score ≥ 11 in the first trimester as an indication of depression according to Bergink and colleagues (2011); **a two-way between-groups analysis of variance revealed a main effect of depression, p < 0.001 (error bars reflect standard error of the mean).

The multivariate model containing all biological, psychological and demographic measures was significant: $\chi^2(5, N = 1682) = 63.49$, p < 0.001. As shown in Table 4, depression and high hCG were independently related to high NVP while (sub)clinical hyperthyroidism was not. Moreover, the confounders history of depression, younger age and multiparity were also significantly and independently related to high NVP. The strongest predictor of high NVP was a high EDS score (i.e. ≥ 11 , indication of depression) between 12 and 14 weeks of gestation, with an OR of 1.67 (95% CI = 1.15–2.43; see Table 4).

Discussion

The current study showed that high hCG levels as well as a history of depression and elevated depressive symptoms between 12 and 14 weeks of gestation are independently related to NVP in the first trimester of pregnancy. Also, multiparous women and younger women had an increased risk of reporting high NVP. Thyroid function, more specifically (sub)clinical hyperthyroidism, was not related to high NVP. These findings indicate that hCG and depression have additive effects on NVP during pregnancy.

We found a significant correlation between hCG and the severity of NVP, but the magnitude of this association was small (r = 0.06, p = 0.022). This finding is consistent with the variability of the correspondence between hCG and HG reported in the literature (Niebyl, 2010; O'Donnell *et al.*, 2016). Moreover, more than half of the 0.4% women with HG showed only moderately elevated pregnancy hCG levels, although this observation is limited to six women. The combination of high hCG levels with depression may be important to identify women at risk of developing NVP during pregnancy.

The finding that (low) TSH was not related to NVP might be explained by hCG acting as a thyroid regulator during pregnancy, because of the production of sub-units of hCG that are potent stimulators of the thyroid gland (Glinoer, 1997; Verberg *et al.*, 2005). In conjunction with this, we found a significant but modest relation between TSH and hCG. Also, the regression analysis showed that high hCG rather than (sub)clinical hyperthyroidism (low TSH and normal to high FT4) was related to high NVP.

Table 4. Adjusted	ORs for the	association	of	psychological	and	biological
factors associated	with high NVF	P scores, $N = 1$	168	2		

	OR (95% CI) ^a	р
High hCG	1.47 (1.11–1.95)	0.007**
(Sub)clinical hyperthyroidism	0.90 (0.39–2.11)	0.81
High EDS score (≥11, indication of depression)	1.67 (1.15–2.43)	0.008**
History of depression	1.53 (1.11–2.11)	0.01*
Age (years)	0.91 (0.87-0.94)	<0.001**
BMI (kg/m ²)	1.03 (0.99–1.06)	0.12
High level of education	0.85 (0.65–1.11)	0.24
Smoking	0.61 (0.35-1.06)	0.08
Unplanned pregnancy	0.86 (0.51-1.45)	0.56
Multiparity	1.47 (1.12–1.92)	0.005**

^aORs are based on the multivariable model in which high NVP is the dependent variable and all other variables are the mutually adjusted independent variables.

High NVP, PUQE score ≥ 9 (based on M + 1 s.p.); OR, adjusted odds ratio; CI, confidence interval; high hCG, defined as log hCG level in upper quartile; (sub)clinical hyperthyroidism = women with overt hyperthyroidism (TSH < 2.5th and FT4 > 97.5th percentile) or subclinical hyperthyroidism (TSH < 2.5th percentile and FT4 within reference range), reference limits assessed in TPO-Ab negative women (≤35 IU/mL); EDS, Edinburgh Depression Scale; high EDS score, ≥11 is an indication of depression in the first trimester according to Bergink and colleagues (2011); BMI, body mass index; high level of education, HBO/University (in Dutch education system); **p < 0.01, *p < 0.05.

Regarding psychological determinants, nausea is a potential somatisation symptom of distress and depression in general (Walker *et al.*, 1990; Haug *et al.*, 2002). Therefore, when assessing the severity of NVP it is important to adjust for the existence of (symptoms of) depression. The current study confirmed that depression, before pregnancy and between 12 and 14 weeks of gestation, is related to high NVP. This is in line with the theory of a cognitive component of NVP (Goodwin, 2002). It is also possible that depression is 'reactive' to NVP. The multivariable analysis investigating the combined effect of high hCG and depression between 12 and 14 weeks of gestation showed that NVP symptoms were higher in women with depression, regardless of the hCG level. Moreover, high EDS between 12 and 14 weeks of gestation was the strongest predictor of high NVP. These findings indicate that a psychobiological model is needed to optimally explain NVP.

The observed association between younger age and high NVP has been reported in the literature before (Klebanoff et al., 1985). The literature regarding an association of NVP with parity is inconclusive: both primiparity (Klebanoff et al., 1985; Latva-Pukkila et al., 2010) and multiparity (Källén et al., 2003) have been reported as determinants for NVP. However, studies that found a relation with primiparity suffered from methodological flaws, such as operationalising NVP by reporting only one symptom of nausea or vomiting. Moreover, inconclusive data were used to define parity (gravidity instead of parity) resulting in difficulty to compare data of the existing literature (Einarson et al., 2007). We found multiparity to be significantly related to high NVP. The finding that women who report NVP in one pregnancy are more likely to report NVP in subsequent pregnancies, supports this (Klebanoff et al., 1985; Einarson et al., 2007). We found no relation between high NVP and smoking status, BMI or unplanned pregnancies. In the literature, conflicting results are mentioned regarding these factors. Källén and colleagues (2003) found that in particular smoking before pregnancy is associated with a decreased risk for NVP. We only assessed smoking status during pregnancy, what might explain why we did not find a relation. Regarding BMI, our sample had relatively few women with mild obesity [8.7%, BMI (kg/m^2) > 30] or extreme obesity [0.2%, BMI (kg/m^2) > 40] compared to the general population in The Netherlands (National Institute for Health and Environment, 2017), resulting in low statistical power to detect weight-related factors involved in NVP.

A unique strength of the current study is the inclusion of both biological and psychological factors into one design. In addition, the operationalisation of these factors is a major strength of the current study. That is, instead of using the PUQE-12 for the previous 12 h, we used the PUQE evaluating the severity of NVP symptoms during the entire first trimester. A study of Lacasse and colleagues (2008) underlined the use of a modified index that covers the entire first trimester because of substantial concordance with the PUQE-12 and the relationship with QOL. We consider this approach as a more reliable way of looking at a possible relation between endocrine factors and NVP. HCG shows a gradual increase from conception until 10-14 weeks of gestation (Niebyl, 2010). Similarly, the pregnancy specific changes of thyroid hormones do occur over a period of weeks rather than hours (Glinoer, 1997). Evaluating a possible association between hCG, thyroid function and NVP during a period of hours does not reflect the physiological pattern of hCG and/or thyroid hormones. Also, if the PUQE questions would have been restricted to the previous 12 h, women who had serious symptoms of nausea and vomiting earlier during pregnancy, including the women with HG, would not have been able to correctly report symptoms of NVP. No Cronbach's α of the English PUQE could be found in the literature, which makes it difficult to compare with the reliability of the original PUQE. An α of 0.85 is found in a study of Birkeland and colleagues (2015), using a translated Norwegian PUQE. However, these investigators used a small sample of hospitalised women due to HG. We investigated a large sample of healthy pregnant women with a whole spectrum of NVP symptoms. The relatively low internal consistency of $\alpha = 0.67$ in the current study partially reflects the short (three-item) scale format of the PUQE as this metric is dependent on the number of items in a scale.

Another strength of the study is the large sample of 1682 women that was fairly representative for the general pregnant population in The Netherlands, regarding important (obstetric) features such as unplanned pregnancy, age and depression (Central Office of Statistics, 2015, 2017). With regard to ethnic subgroups and education, the current cohort is not optimally representative of the general population. Only women with understanding of the Dutch language were included. The high number of highly educated women in the current study should be regarded in light of their age and the area where the study was undertaken. The education level for all women living around Eindhoven at this (young) age is approximately equal to that of women in the used sample (Central Office of Statistics, 2017). The finding in the current study that education level was not related to high NVP is in line with other reports (Koren *et al.*, 2002).

This study has also limitations. First, we did not ask about nutritional intake habits and did not evaluate the possible impact of diet on NVP. In addition, the cut-off value for hCG (75th percentile) may be sample-specific. However, this sample is comparable to the general obstetric practice in The Netherlands. The correspondence of hCG values between the sample of the current study and a previous study of 568 pregnant women from the same

area, substantiates this (Pop et al., 2018). Both studies used similar hCG assessment methods and similar in- and exclusion criteria. Furthermore, we used a large population-based study of 8195 pregnant women in The Netherlands (Korevaar et al., 2015) as a reference and found similar hCG values (current study: Md = 58 000 IU/L; Korevaar and colleagues: $Md_{12 \text{ weeks}} = 56\ 004\ \text{IU/L}$, $Md_{13 weeks} = 52 367 IU/L$, $Md_{14 weeks} = 47 267 IU/L$). As far as we know, there are no internationally agreed upon normative data for hCG in the first trimester of pregnancy. Finally, the use of a cross-sectional design prevents us from drawing any causal relationships. For example, women who reported serious problems resulting in referral to their GP and/or gynaecologist in the weeks before completing the PUQE showed higher depression scores between 12 and 14 weeks of gestation. It is unclear whether they were depressed as a result of previously occurring severe NVP symptoms or because of other reasons. Additional research is needed to further understand the pathophysiology of NVP, to decide what biological factors contribute to the aetiology of NVP and to explore what pathway relates NVP to depression. For example, it would be interesting to examine the possible influence of cortisol as a hypothalamic-pituitary axis hormone in addition to TSH and FT4. Since NVP is thought to be multifactorial, prospective research should analyse different biological and psychological variables in one design to ascertain the determinants of NVP. Other psychological factors, for example anxiety, could be examined in relation to NVP as well. Our findings support the theory of a cognitive component in NVP and emphasise the need for a multidisciplinary approach. From a clinical perspective, the observed association between elevated depressive symptoms and NVP indicates that monitoring, and when needed treating, depression may have beneficial effects for NVP. Screening for depressive symptoms in women with NVP and referral for psychological interventions could possibly lead to a reduction of

In conclusion, the current study shows that both hCG and psychological factors are related to the severity of NVP. This underlines the need for using a psychobiological model for future NVP research and clinical interventions.

symptoms of NVP and thereby less reduction of QOL, limitation

Author ORCIDs. (D) Guus W.F. Dekkers, 0000-0003-2833-7433.

Acknowledgements. We thank all the midwives of the participating midwifery practices around Eindhoven for contributing to the recruitment of participants.

Financial support. This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflict of interest. None.

of functioning and costs.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References

- Andersson L, Sundström-Poromaa I, Wulff M, Åström M and Bixo M (2004) Implications of antenatal depression and anxiety for obstetric outcome. Obstetrics & Gynecology 104, 467–476.
- Attard CL, Kohli MA, Coleman S, Bradley C, Hux M, Atanackovic G and Torrance GW (2002) The burden of illness of severe nausea and vomiting of pregnancy in the United States. *American Journal of Obstetrics and Gynecology* 186, 220–227.

- Bergink V, Kooistra L, Lambregtse-van den Berg MP, Wijnen H, Bunevicius R, van Baar A and Pop V (2011) Validation of the Edinburgh depression scale during pregnancy. *Journal of Psychosomatic Research* 70, 385–389.
- Birkeland E, Stokke G, Tangvik RJ, Torkildsen EA, Boateng J, Wollen AL, Albrechtsen S, Flaatten H and Trovik J (2015) Norwegian PUQE (pregnancy-unique quantification of emesis and nausea) identifies patients with hyperemesis gravidarum and poor nutritional intake: a prospective cohort validation study. *PLoS ONE* **10**, 1–15.
- Buckwalter JG and Simpson SW (2002) Psychological factors in the etiology and treatment of severe nausea and vomiting in pregnancy. American Journal of Obstetrics and Gynecology 186, 210–214.
- Central Office of Statistics (Centraal Bureau voor de Statistiek) (2015). Documentation report Perinatal Registration Netherlands (PRN) (Documentatierapport Perinatale Registratie Nederland (PRN)). Available at https://www.cbs.nl/nl-nl/onze-diensten/maatwerk-en-microdata/zelf-onderzoekdoen/microdatabestanden/-/media/70ec2e4523bf449586dd9a2f85862296. ashx (Accessed April 2017).
- Central Office of Statistics (Centraal Bureau voor de Statistiek) (2017). Statline. Available at http://statline.cbs.nl/ (Accessed April 2017).
- Chou FH, Lin LL, Cooney AT, Walker LO and Riggs MW (2003) Psychosocial factors related to nausea, vomiting, and fatigue in early pregnancy. *Journal of Nursing Scholarship* 35, 119–125.
- Cohen J (1992) A power primer. Psychological Bulletin 112, 155-159.
- Cox JL, Chapman G, Murray D and Jones P (1996) Validation of the Edinburgh postnatal depression scale (EPDS) in non-postnatal women. *Journal of Affective Disorders* 39, 185–189.
- Ebrahimi N, Maltepe C, Bournissen FG and Koren G (2009) Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. *Journal of Obstetrics and Gynaecology Canada* 31, 803–807.
- Einarson TR, Navioz Y, Maltepe C, Einarson A and Koren G (2007) Existence and severity of nausea and vomiting in pregnancy (NVP) with different partners. *Journal of Obstetrics and Gynaecology* **27**, 360–362.
- Gadsby R, Barnie-Adshead AM and Jagger C (1993) A prospective study of nausea and vomiting during pregnancy. *British Journal of General Practice* 43, 245–248.
- Gadsby R, Barnie-Adshead AM and Jagger C (1997) Pregnancy nausea related to women's obstetric and personal histories. *Gynecologic and Obstetric Investigation* 43, 108–111.
- Glinoer D (1997) The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. *Endocrine Reviews* 18, 404–433.
- Goodwin TM (2002) Nausea and vomiting of pregnancy: an obstetric syndrome. American Journal of Obstetrics and Gynecology 186, 184–189.
- Haug TT, Mykletun A and Dahl AA (2002) The prevalence of nausea in the community: psychological, social and somatic factors. *General Hospital Psychiatry* 24, 81–86.
- Jueckstock JK, Kaestner R and Mylonas I (2010) Managing hyperemesis gravidarum: a multimodal challenge. *BioMed Central Medicine* 8, 1–12.
- Källén B, Lundberg G and Åberg AE (2003) Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy. Acta Obstetricia et Gynecologica Scandinavica 82, 916–920.
- Kelly RH, Russo J and Katon W (2001) Somatic complaints among pregnant women cared for in obstetrics: normal pregnancy or depressive and anxiety symptom amplification revisited? *General Hospital Psychiatry* 23, 107–113.
- Klebanoff MA, Koslowe PA, Kaslow R and Rhoads GG (1985) Epidemiology of vomiting in early pregnancy. *Obstetrics & Gynecology* 66, 612–616.
- Koren G, Magee L, Attard C, Kohli M, Atanackovic G, Bishai R, Chandra K, Navoiz Y and Maltepe C (2001) A novel method for the evaluation of the severity of nausea and vomiting of pregnancy. *European Journal of Obstetrics & Gynecology and Reproductive Biology* **94**, 31–36.

- Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y and Einarson A (2002) Motherisk–PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. *American Journal of Obstetrics and Gynecology* 186, 228–231.
- Korevaar TIM, Steegers EAP, de Rijke YB, Schalekamp-Timmermans S, Visser WE, Hofman A, Jaddoe VWV, Tiemeier H, Visser TJ, Medici M and Peeters RP (2015) Reference ranges and determinants of total hCG levels during pregnancy: the generation R study. *European Journal of Epidemiology* 30, 1057–1066.
- Lacasse A, Rey E, Ferreira E, Morin C and Bérard A (2008) Nausea and vomiting of pregnancy: what about quality of life? *British Journal of Obstetrics and Gynaecology* 115, 1484–1493.
- Lacroix R, Eason E and Melzack R (2000) Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity, and patterns of change. American Journal of Obstetrics and Gynecology 182, 931–937.
- Latva-Pukkila U, Isolauri E and Laitinen K (2010) Dietary and clinical impacts of nausea and vomiting during pregnancy. *Journal of Human Nutrition and Dietetics* 23, 69–77.
- Locock L, Alexander J and Rozmovits L (2008) Women's responses to nausea and vomiting in pregnancy. *Midwifery* 24, 143–152.
- Medici M, Korevaar TIM, Visser WE, Visser TJ and Peeters RP (2015) Thyroid function in pregnancy: what is normal? *Clinical Chemistry* 61, 704–713.
- National Institute for Health and Environment (2017). (Rijksinstituut voor Volksgezondheid en Milieu) Overweight adults (Overgewicht volwassenen). Available at https://www.volksgezondheidenzorg.info (Accessed May 2017).
- Niebyl JR (2010) Nausea and vomiting in pregnancy. New England Journal of Medicine 363, 1544–1550.
- O'Donnell A, McParlin C, Robson SC, Beyer F, Moloney E, Bryant A, Bradley J, Muirhead C, Nelson-Piercy C, Newbury-Birch D, Norman J, Simpson E, Swallow B, Yates L and Vale L (2016) Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment. *Health Technology Assessment* 20, 1–268.
- Pop VJ, Komproe IH and van Son MJ (1992) Characteristics of the Edinburgh post natal depression scale in The Netherlands. *Journal of Affective Disorders* 26, 105–110.
- Pop V, Broeren M, Wijnen H, Endendijk J, van Baar A, Wiersinga W and Williams GR (2018) Longitudinal trajectories of gestational thyroid function: a new approach to better understand changes in thyroid function. *The Journal of Clinical Endocrinology & Metabolism* 103, 2889–2900.
- Swallow BL, Lindow SW, Masson EA and Hay DM (2004) Psychological health in early pregnancy: relationship with nausea and vomiting. *Journal* of Obstetrics and Gynaecology 24, 28–32.
- Tan JYL, Loh KC, Yeo GSH and Chee YC (2002) Transient hyperthyroidism of hyperemesis gravidarum. British Journal of Obstetrics and Gynaecology 109, 683–688.
- Truijens SEM, Meems M, Kuppens SMI, Broeren MAC, Nabbe KCAM, Wijnen HA, Oei SG, van Son MJM and Pop VJM (2014) The HAPPY study (holistic approach to pregnancy and the first postpartum year): design of a large prospective cohort study. *BioMed Central Pregnancy and Childbirth* 14, 1–12.
- Verberg MFG, Gillott DJ, Al-Fardan N and Grudzinskas JG (2005) Hyperemesis gravidarum, a literature review. *Human Reproduction Update* 11, 527–539.
- Vikanes Å, Skjaerven R, Grjibovski AM, Gunnes N, Vangen S and Magnus P (2010) Recurrence of hyperemesis gravidarum across generations: population based cohort study. British Medical Journal 340, 1–5.
- Walker EA, Roy-Byrne PP and Katon WJ (1990) Irritable bowel syndrome and psychiatric illness. The American Journal of Psychiatry 147, 565–572.
- Yates J (2004) Nausea and vomiting of pregnancy: Q&A with T. Murphy Goodwin. OBG Management 16, 54–67.